Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 8/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | CKS1B | P61024 | 4/20 | 0.33 |
| ▸ | SKP1 | P63208 | 4/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615035 | 0.97 | GHSR (0.35) | GHSRRETATRCKS1BSKP1 | |
| SCHEMBL618532 | 0.85 | CKS1B (0.42) | RETATRCKS1BSKP1SKP2 | |
| SCHEMBL615205 | 0.84 | CKS1B (0.47) | RETATRCKS1BSKP1SKP2 | |
| SCHEMBL614750 | 0.80 | ATR (0.37) | RETATRCKS1BSKP1SKP2 | |
| SCHEMBL616677 | 0.78 | IDH1 (0.40) | ATRCKS1BSKP1SKP2 | |
| SCHEMBL617707 | 0.78 | ATR (0.34) | ATRCKS1BSKP1SKP2 | |
| SCHEMBL10289913 | 0.78 | ATR (0.34) | RETATRCKS1BSKP1SKP2 | |
| SCHEMBL615316 | 0.78 | ATR (0.43) | ATRALDH1A1 | |
| SCHEMBL615273 | 0.78 | ATR (0.35) | RETATRCKS1BSKP1SKP2 | |
| SCHEMBL617195 | 0.76 | ATR (0.37) | RETATRCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-24 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | GHSR 4016/4885RET 505/4885ATR 1/4885 |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | GHSR 4016/4885RET 505/4885ATR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.